OTCPK:SWTUY (Sweden)
Business Description
Swedish Orphan Biovitrum AB
Tomtebodavagen 23 A, Solna, Stockholm, SWE, SE-112 76
Compare
Compare
Traded in other countries / regions
B6E.Germany
•
SOBI.Mexico
•
SOBI.Sweden
•
0MTD.UK
•
SWTUY.USA
Description
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement programs in 2006. Biovitrum also acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched its hemophilia products Alprolix and Eloctate in Europe in 2016. In 2019, Sobi acquired rights to rare disease drug Gamifant, U.S. rights to Astra's RSV prevention drug Synagis, and rights to thrombocytopenia drug Doptelet (with the Dova acquisition). In 2020, new collaborations brought rights to gout drug pegadricase and complement-mediated disease drug Aspaveli.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.04 | |||||
| Equity-to-Asset | 0.5 | |||||
| Debt-to-Equity | 0.41 | |||||
| Debt-to-EBITDA | 1.76 | |||||
| Interest Coverage | 10.41 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 2.31 | |||||
| Beneish M-Score | -2.32 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 15.7 | |||||
| 3-Year EBITDA Growth Rate | 12.9 | |||||
| 3-Year EPS without NRI Growth Rate | 0.4 | |||||
| 3-Year FCF Growth Rate | 45.4 | |||||
| 3-Year Book Growth Rate | 32.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate Industry Rank | 7.97 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | 9.01 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 6-1 Month Momentum % | -15.2 | |||||
| 12-1 Month Momentum % | 14.86 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.02 | |||||
| Quick Ratio | 0.59 | |||||
| Cash Ratio | 0.05 | |||||
| Days Inventory | 270.74 | |||||
| Days Sales Outstanding | 65.8 | |||||
| Days Payable | 46.14 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -3 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 74.16 | |||||
| Operating Margin % | 19.97 | |||||
| Net Margin % | 14.41 | |||||
| ROE % | 11.01 | |||||
| ROA % | 5.27 | |||||
| ROIC % | 6.14 | |||||
| ROC (Joel Greenblatt) % | 244.61 | |||||
| ROCE % | 8.4 | |||||
| Years of Profitability over Past 10-Year | 7 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 27.64 | |||||
| Forward PE Ratio | 28.41 | |||||
| PE Ratio without NRI | 27.64 | |||||
| Shiller PE Ratio | 44.59 | |||||
| Price-to-Owner-Earnings | 62.2 | |||||
| PEG Ratio | 0.87 | |||||
| PS Ratio | 3.98 | |||||
| PB Ratio | 2.84 | |||||
| Price-to-Free-Cash-Flow | 20.39 | |||||
| Price-to-Operating-Cash-Flow | 15.94 | |||||
| EV-to-EBIT | 23.69 | |||||
| EV-to-EBITDA | 14.04 | |||||
| EV-to-Revenue | 4.5 | |||||
| EV-to-FCF | 23.01 | |||||
| Price-to-Projected-FCF | 2.4 | |||||
| Price-to-Median-PS-Value | 0.66 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.11 | |||||
| Earnings Yield (Greenblatt) % | 4.22 | |||||
| Forward Rate of Return (Yacktman) % | 21.06 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with OTCPK:SWTUY
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1,874.876 | ||
| EPS (TTM) ($) | 0 | ||
| Beta | 0 | ||
| Volatility % | 50.81 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR ($) | 0 | ||
| 20-Day SMA ($) | 0 | ||
| 12-1 Month Momentum % | 14.86 | ||
| 52-Week Range ($) | 18.5 - 31.96 | ||
| Shares Outstanding (Mil) | 294.09 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Swedish Orphan Biovitrum AB Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||